Casolaro et al
" Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML."
but evidence is imposing PLGC1 because of its critical interactions with Gerb2 and DVL1, the FLT
and may be more importantly with ETS.
*Anti-NHE1/CHP could have a larger impact in resistant Thyroid cancers theoritically, or diseases where the Calcineurin/NFAT have a stronger role?
No comments:
Post a Comment